Emergent Biosolutions EBITDA 2010-2022 | EBS

Emergent Biosolutions ebitda from 2010 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Emergent Biosolutions Annual EBITDA
(Millions of US $)
2021 $481
2020 $552
2019 $228
2018 $153
2017 $169
2016 $144
2015 $177
2014 $122
2013 $62
2012 $41
2011 $41
2010 $80
2009 $45
Emergent Biosolutions Quarterly EBITDA
(Millions of US $)
2022-03-31 $38
2021-12-31 $308
2021-09-30 $-1
2021-06-30 $49
2021-03-31 $125
2020-12-31 $288
2020-09-30 $91
2020-06-30 $155
2020-03-31 $17
2019-12-31 $106
2019-09-30 $99
2019-06-30 $22
2019-03-31 $0
2018-12-31 $37
2018-09-30 $34
2018-06-30 $79
2018-03-31 $3
2017-12-31 $67
2017-09-30 $58
2017-06-30 $18
2017-03-31 $25
2016-12-31 $61
2016-09-30 $46
2016-06-30 $7
2016-03-31 $30
2015-12-31 $95
2015-09-30 $72
2015-06-30 $30
2015-03-31 $-20
2014-12-31 $84
2014-09-30 $40
2014-06-30 $16
2014-03-31 $-19
2013-12-31 $29
2013-09-30 $23
2013-06-30 $19
2013-03-31 $-9
2012-12-31 $28
2012-09-30 $13
2012-06-30 $11
2012-03-31 $-10
2011-12-31 $48
2011-09-30 $4
2011-06-30 $22
2011-03-31 $-33
2010-12-31 $37
2010-09-30 $22
2010-06-30 $16
2010-03-31 $4
2009-12-31 $5
2009-09-30 $-3
2009-06-30 $24
2009-03-31 $19
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.625B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00